All AbMole products are for research use only, cannot be used for human consumption.
Idarubicin inhibits CYP450 2D6. Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively. Idarubicin is able to overcome P-glycoprotein-mediated multidrug resistance. The high stereospecificity in Idarubicin reduction might result from chiral induction due to the presence of asymmetric centres near to the carbonyl group in Idarubicin.
| Molecular Weight | 533.95 |
| Formula | C26H27NO9.HCl |
| CAS Number | 57852-57-0 |
| Solubility (25°C) | DMSO 60 mg/mL Water 6 mg/mL |
| Storage | 2-8°C, dry, protect from light, sealed |
| Related Topoisomerase Products |
|---|
| Amonafide
Amonafide is a unique ATP-independent Topo II inhibitor that is being studied in the treatment of cancer. |
| Idarubicin
Idarubicin is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells. |
| Dexrazoxane hydrochloride
Dexrazoxane HCl (ICRF-187, ADR-529, DXZ) is an iron chelator that can be used to prevent DOX-induced cardiotoxicity. |
| Irinotecan Hydrochloride Trihydrate
Irinotecan hydrochloride trihydrate is a potent inhibitor of DNA topoisomerase I. |
| Topotecan hydrochloride
Topotecan hydrochloride is a topoisomerase I inhibitor and an apoptosis inducer. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
